Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tischner, Hartmut
NCT06211049: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea	Active, not recruiting	3	286	Europe, RoW	Vitex agnus-castus BNO 1095 (20 mg), Placebo	Bionorica SE, FGK Clinical Research GmbH	Primary Dysmenorrhea	03/25	03/25
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older	Completed	3	7741	Europe, Canada, US, RoW	Investigational aQIVc, licensed QIVr, licensed aQIV	Seqirus	Influenza, Human	03/24	01/25
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.	Terminated	N/A	715	Europe, Japan, US, RoW	THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence	Philip Morris Products S.A.	COPD, Smoking, Tobacco Use	09/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tischner, Hartmut
NCT06211049: Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea	Active, not recruiting	3	286	Europe, RoW	Vitex agnus-castus BNO 1095 (20 mg), Placebo	Bionorica SE, FGK Clinical Research GmbH	Primary Dysmenorrhea	03/25	03/25
NCT06015282: The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older	Completed	3	7741	Europe, Canada, US, RoW	Investigational aQIVc, licensed QIVr, licensed aQIV	Seqirus	Influenza, Human	03/24	01/25
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.	Terminated	N/A	715	Europe, Japan, US, RoW	THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence	Philip Morris Products S.A.	COPD, Smoking, Tobacco Use	09/24	09/24